7 195

Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome

Authors
 Shin Hye Kim  ;  So-Hee Eun  ;  Hoon-Chul Kang  ;  Eun Ji Kwon  ;  Jung Hye Byeon  ;  Young-Mock Lee  ;  Joon Soo Lee  ;  Baik-Lin Eun  ;  Heung Dong Kim 
Citation
 Seizure - European Journal of Epilepsy, Vol.21(4) : 288-291, 2012 
Journal Title
 Seizure - European Journal of Epilepsy 
ISSN
 1059-1311 
Issue Date
2012
Abstract
PURPOSE: To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). METHODS: The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included 4 weeks of scheduled titrated doses and a 12-week maintenance phase with a target dose of 20-40 mg/kg rufinamide, adjusted according to its effectiveness and tolerability after a baseline period of 4 weeks. The primary outcome was measured by the seizure-reduction rate according to individual seizure type over the 12-week maintenance period. RESULTS: One hundred and twenty-eight patients with LGS who were determined to be unresponsive to one or more antiepileptic drugs or dietary therapy were enrolled. Of the 128 patients enrolled, 112 (87.5%) completed the study. After add-on rufinamide treatment, 46 patients (35.9%) achieved a more than 50% reduction in seizure frequency and 10 (7.8%) patients became seizure-free. When we identified those who responded with an at least 50% reduction in seizure frequency, 39.4% of the responders reported reductions in convulsive seizures, 36.4% in drop attacks, 33.3% in myoclonic seizures, and 20.0% in epileptic spasms. Overall, 32.8% of patients reported adverse effects, which were mostly mild and transient in nature. The most common adverse effects were fatigue (15 patients, 11.7%) and poor appetite (9 patients, 7.0%). Twenty-one (16.4%) patients experienced an increased seizure frequency. CONCLUSIONS: Rufinamide appears to be a safe and effective adjuvant treatment for many cases of intractable LGS.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/91843
Full Text
http://www.sciencedirect.com/science/article/pii/S1059131112000453
DOI
10.1016/j.seizure.2012.02.006
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실)
Yonsei Authors
강훈철(Kang, Hoon Chul) ORCID logo https://orcid.org/0000-0002-3659-8847
권은지(Kwon, Eun Ji)
김신혜(Kim, Shin Hye)
김흥동(Kim, Heung Dong)
은호선(Eun, Ho Seon)
이영목(Lee, Young Mock)
이준수(Lee, Joon Soo)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse